Table 6.

Changes in mPSC amplitude on GnRH neurons upon application of Exendin-4 after pretreatment with various antagonists or inhibitors.

	Basal amplitude (pA)	During antagonists and inhibitors (pA)	Change after Ex-4
			in pA	in %
Ex3(9–39)	41 ± 6.2	39 ± 4.8	37 ± 5.2	96 ± 11.5
L-NAME	35 ± 7.6	37 ± 6.3	37 ± 5.3	102 ± 12.2
AM251	32 ± 8.8	37 ± 6.4	37 ± 4.8	100 ± 11.6
L-NAME + AM251	39 ± 6.7	35 ± 7.2	35 ± 5.0	99 ± 8.7
GDP- βS	35 ± 6.1	36 ± 4.9	33 ± 5.7	93 ± 9.3
CPTIO	42 ± 5.5	38 ± 5.9	41 ± 6.1	110 ± 15.4
intraNPLA + AM251	43 ± 7.0	39 ± 5.7	41 ± 4.9	106 ± 12.3
L-NAME + AMG9810	43 ± 7.0	39 ± 5.7	41 ± 6.3	106 ± 12.3
NPLA + PF3845	40 ± 5.9	42 ± 4.5	40 ± 7.1	95 ± 8.9